Top Markets
Coin of the day
BioNexus Gene Lab Corp. BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp.

BGLC
Rank in Stocks #35594
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala... BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
Share Price
$1.50
Last synced: 2026-09-21
Market Cap
$3.63M
Change (1 day)
-4.46%
Change (1 year)
-72.68%
Country
MY
Trade BioNexus Gene Lab Corp. (BGLC)

Category

Revenue for BioNexus Gene Lab Corp. (BGLC)
Revenue in Jun 2026 TTM: $3.13M
According to BioNexus Gene Lab Corp. latest financial reports the company's current revenue (TTM) is $3.13M. In 2023 the company made a revenue of $9.77M a decrease compared to the revenue in the year 2022 that was $10.93M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for BioNexus Gene Lab Corp. from 2016 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $3.13M -67.13%
2024 $9.51M -2.66%
2023 $9.77M -10.60%
2022 $10.93M -18.21%
2021 $13.36M 17.31%
2020 $11.39M 8,872.03%
2019 $126.96K -40.21%
2018 $212.33K 97.18%
2017 $107.68K 0.00%
2016 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$18.85B 602,635.06%
US
$8.75B 279,736.03%
US
- -
US
$25.01B 799,904.86%
US
- -
US